On 7 November 2025, Medical Dialogues reported that Zydus Lifesciences has received tentative approval from the FDA for olaparib tablets, 100 mg and 150 mg, referencing AstraZeneca/MSD’s Lynparza®.
In February 2025, AstraZeneca and MSD’s Lynparza® was accepted in Scotland for reimbursement for the treatment of adults with BRCA1 or 2 mutated HER2-negative advanced breast cancer, who have already received appropriate treatments for their type of breast cancer.
In December 2024, AstraZeneca and MSD announced positive results for Lynparza® in the treatment of breast cancer, demonstrating a reduced risk of death by 28%.